BOSTON, Oct. 19, 2018 /PRNewswire/ -- BERG LLC, a
Boston-based biopharmaceutical
company that merges biology with technology to map the nature of
diseases, today announced the presentation of three posters on the
progression of its oncology and artificial intelligence
(AI)/Biomarker portfolio at the European Society of Medical
Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany.
Key presentation highlights include:
- Final study data from a phase 1 clinical trial of BPM 31543 for
prevention of chemotherapy-induced-alopecia (CIA)
- Interim data on BPM 31510-IV for advanced pancreatic cancer
from a phase 2 clinical trial
- AI driven pipeline using multi-omic analysis for precision
oncology
"The data accepted for presentation further reinforce the power
and value of our proprietary Interrogative Biology platform
and promising early stage pipeline for the treatment of advanced
pancreatic cancer and chemotherapy-induced alopecia, among other
oncologic conditions," said Niven R.
Narain, Ph.D., BERG Co-founder, President and Chief
Executive Officer. "By taking a Back to Biology approach in
combination with artificial intelligence, we are armed with greater
understanding of disease biomarkers to guide our discovery and
development efforts to effectively achieve therapeutic response and
patient benefit through novel treatment options."
Details of the poster presentations are as follows and are
available via the ESMO 2018 Annual Congress website:
Title: Streamlining Multi-Omic and Artificial
Intelligence Analysis Through Interrogative Biology® and
bAIcis® for Translational Precision Medicine
Applications in Clinical Oncology
Presentation Number: 1886P
Date and Time: October 20,
2018, 12:30 – 1:30 p.m.
CEST
Location: Hall A3 - Poster Area Networking Hub
Title: A Phase 2 Clinical Investigation of BPM 31510-IV
(Ubidecarenone) in Patients with Advanced Pancreatic Cancer
Presentation Number: 790TiP
Date and Time: October 21,
2018, 12:45 – 1:45 p.m.
CEST
Location: Hall A3 - Poster Area Networking Hub
Title: A Phase I Safety Study of Topical Calcitriol (BPM
31543) for the Prevention of Chemotherapy-Induced Alopecia (CIA):
Final Study Results
Presentation Number: 1694P
Date and Time: October 22, 2018, 12:45 – 1:45 p.m. CEST
Location: Hall A3 - Poster Area Networking Hub
About BPM 31510
Cancer cells alter metabolism to generate energy from
non-mitochondrial pathways to support uncontrolled growth. This
allows the cancer cells to escape molecular mechanisms controlling
cell death. BPM 31510 is a first-in-class molecule that
specifically targets the dysregulated metabolism observed in
cancer. BPM 31510, by targeting metabolism in cancer cells,
re-engages the mitochondria to generate energy, shifting metabolism
to that observed in the normal cell. The effect of BPM 31510 on
metabolism results in the reactivation of pathways that detect cell
damage, triggering apoptosis or programmed cell death.
About BPM 31543
Chemotherapy-induced-alopecia (CIA) is
a side effect of cytotoxic chemotherapy agents for which there are
currently no available therapeutic interventions. BPM 31543
(calcitriol) is a first-in-class topical compound in clinical
development for the treatment of chemotherapy-induced hair loss
(alopecia). BPM 31543 influences gene expression in hair follicles,
keeping cells in the growth phase and making them resistant to
chemotoxic agents. The safety and tolerability of BPM 31543 has
been established in a Phase 1 clinical trial and efforts are
underway for next steps in clinical development.
About BERG
BERG LLC is a clinical-stage, artificial
intelligence-powered biotech leveraging its proprietary platform,
Interrogative Biology®, to map disease and revolutionize
treatments across oncology, neurology and rare diseases. By taking
a Back to Biology™ approach, BERG is able to identify
critical biomarkers that can accelerate the discovery and
development of treatments aimed at the most promising therapeutic
targets and pathways. BERG has leveraged both Interrogative
Biology® and traditional R&D methods to develop a
robust pipeline of first-in-class product candidates and
diagnostics that advance bold innovations that have the potential
to improve patient lives. To learn more about how we're enabling
bold innovation, visit berghealth.com.
Media Contact:
Chris Dougherty
Ogilvy
917-515-9876
BERG@Ogilvy.com
BERG Investor Contact:
Molly
Cameron
BERG
617-588-1000
Molly.Cameron@BergHealth.com
Logo - https://mma.prnewswire.com/media/554023/BERG_Logo.jpg